STOCK TITAN
  1. Home
  2. News
  3. SOPH

SOPHiA GENETICS SA Ordinary Shares - SOPH STOCK NEWS

Welcome to our dedicated page for SOPHiA GENETICS SA Ordinary Shares news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA GENETICS SA Ordinary Shares stock.

SOPHiA GENETICS SA (Nasdaq: SOPH) is a leader in the field of data-driven medicine, leveraging cutting-edge technology to advance healthcare. Based in Switzerland, the company is renowned for its high medical standards and precision. SOPHiA GENETICS has built the SOPHiA DDM™ Platform, a cloud-based SaaS platform designed to analyze complex genomic and multimodal data, delivering valuable insights for clinical and life sciences research.

Through its innovative platform, SOPHiA GENETICS supports healthcare professionals in over 100 hospitals globally, enabling them to perform faster and more accurate diagnoses using next-generation sequencing (NGS) analytics. The platform also facilitates knowledge sharing within the largest clinical genomics community.

Recently, SOPHiA GENETICS has made significant strides with several notable partnerships:

  • Unilabs, a prominent European diagnostic provider, adopted the SOPHiA DDM™ Platform to enhance their HRD-status testing capabilities in solid tumors.
  • Syndicate Bio in Nigeria integrated MSK-ACCESS® powered by SOPHiA DDM™, marking the first comprehensive genomic profiling and liquid biopsy availability across Africa.
  • Klinikum Klagenfurt in Austria and Instituto Mário Penna in Brazil have also implemented the platform to advance their cancer diagnostics and treatment planning, particularly in blood-related cancers and disorders.

Financially, SOPHiA GENETICS is recognized for its robust operational execution and business momentum, continually reaffirming its guidance. The company is actively collaborating with tech giants like Microsoft and NVIDIA to develop a streamlined whole genome sequencing (WGS) analytical solution, promising rapid and precise insights aiding clinical decision-making.

SOPHiA GENETICS also launched SOPHiA UNITY, a global consortium to accelerate cancer research by harnessing diverse, high-quality data from leading institutions worldwide. The platform’s advanced AI-based technology and proprietary algorithms will support decision-making and expedite oncology research.

For more information, visit SOPHiAGENETICS.com or connect on LinkedIn, X, Facebook, and Instagram.

News

Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid Disorders

Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) partners with Hôpital Saint-Louis in Paris to implement the SOPHiA DDM™ Platform for research on Myeloid Disorders, aiming to provide data-driven care to patients with MPNs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference

Rhea-AI Summary
SOPHiA GENETICS (NASDAQ: SOPH) CEO Jurgi Camblong, PhD., to present at J.P. Morgan 2024 Healthcare Conference on January 11, 2024, in San Francisco.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
conferences
-
News

SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy Offerings

Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) expands its suite of solutions under SOPHiA DDM™ for Liquid Biopsy, offering MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions to advance oncology research and tumor mutation profiling. Liquid biopsy testing provides an alternative to solid tumor testing by isolating cell-free DNA from blood plasma, allowing for faster, less invasive clinical decisions and simplified monitoring. The company's proprietary unique molecular identifier technology (CUMIN™) promises exceptional performance and reliable results in analyzing cell-free DNA samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
News

SOPHiA GENETICS Announces Expansion of Work with CHU de Nîmes

Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) announces expanded research partnership with CHU de Nîmes, a regional and university hospital in France. CHU de Nîmes will utilize SOPHiA DDM™ Platform for pharmacogenomics research, aiming to personalize medication response based on genetic profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
-
News

SOPHiA GENETICS Expands Relationship with Città della Salute e della Scienza di Torino

Rhea-AI Summary
SOPHiA GENETICS (SOPH) expands its relationship with Città della Salute e della Scienza di Torino, the largest health center in Italy, to further utilize the SOPHiA DDM™ Platform on Microsoft Azure for research on homologous recombination repair (HRR) biomarkers. The cloud-native software company aims to support the hospital's research in various cancer types and rare diseases, revolutionizing data-driven medicine capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
News

The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS

Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), is now live on the SOPHiA DDM™ Platform to advance its research into rare disorders, particularly male fertility. IHG PAS will use SOPHiA DDM™ Whole Exome Solution (WES) for next-generation sequencing (NGS) to accelerate research of inherited diseases, including infertility. The platform provides overnight analysis of WES and a rich knowledge base to help identify variants of interest associated with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
News

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Rhea-AI Summary
SOPHiA GENETICS announced the implementation of MSK-ACCESS liquid biopsy to be commercially available for ordering by healthcare providers through BioReference and GenPath Oncology in 2024. The new offering aims to bring access to world-class liquid biopsy testing to BioReference's customers across the U.S., allowing for less invasive monitoring of cancers and expedited insights for precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Rhea-AI Summary
SOPHiA GENETICS announced that BioReference Health, LLC will implement its technology and add MSK-ACCESS liquid biopsy to its test suite, making it the first laboratory globally to adopt this technology. The offering will be commercially available for ordering by healthcare providers through BioReference and its specialty division, GenPath Oncology, in 2024. The new liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023

Rhea-AI Summary
SOPHiA GENETICS SA (Nasdaq: SOPH) reported financial results for Q3 2023, with revenue of $16.3 million, a 40% YoY growth. Operating loss improved by 30% YoY, and cash burn decreased to $15.8 million. The company reaffirmed its full-year guidance, expecting revenue growth of at least 30% and operating losses below 2022 levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
earnings
News

SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023

Rhea-AI Summary
SOPHiA GENETICS SA to release Q3 2023 financial results on November 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.51%
Tags
earnings

FAQ

What is the current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH)?

The current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH) is $3.65 as of November 1, 2024.

What is the market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH)?

The market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH) is approximately 241.9M.

What does SOPHiA GENETICS do?

SOPHiA GENETICS is a healthcare technology company that leverages AI to analyze complex genomic and multimodal data, providing insights for clinical diagnostics and life sciences research.

What is the SOPHiA DDM™ Platform?

The SOPHiA DDM™ Platform is a cloud-based SaaS solution that analyzes next-generation sequencing (NGS) data and integrates various diagnostic modalities to deliver actionable insights for healthcare providers.

Where is SOPHiA GENETICS based?

SOPHiA GENETICS is headquartered in Switzerland, with a physical presence in France, the United States, and Brazil.

Who are some of SOPHiA GENETICS' partners?

Recent partners include Unilabs in Europe, Syndicate Bio in Nigeria, Klinikum Klagenfurt in Austria, and Instituto Mário Penna in Brazil.

What is SOPHiA UNITY?

SOPHiA UNITY is a data-driven consortium designed to accelerate cancer research globally by bringing together healthcare institutions to share and analyze diverse, high-quality data.

How does SOPHiA GENETICS support precision medicine?

Through its SOPHiA DDM™ Platform, SOPHiA GENETICS enables healthcare providers to perform fast, accurate genetic analyses, facilitating data-driven treatment decisions and advancing precision medicine.

What recent advancements have SOPHiA GENETICS made?

Recent advancements include the integration of their platform by Unilabs for HRD-testing in tumors, the launch of WGS solutions in collaboration with Microsoft and NVIDIA, and the formation of SOPHiA UNITY for cancer research.

What is the company's mission?

SOPHiA GENETICS' mission is to expand access to data-driven medicine globally, using AI to provide world-class care to patients with cancer and rare disorders.

How does SOPHiA GENETICS ensure data privacy and quality?

The company employs advanced bioinformatics and machine learning technologies to ensure high-quality analysis and secure banking of patient DNA sequence data, maintaining stringent privacy standards.

How can I learn more about SOPHiA GENETICS?

For more information, visit their website at SOPHiAGENETICS.com or connect with them on social media platforms like LinkedIn, X, Facebook, and Instagram.

Stock SOPH logo
SOPHiA GENETICS SA Ordinary Shares

Nasdaq:SOPH

SOPH Rankings

#3681 Ranked by Market Cap
N/A Ranked by Dividends

SOPH Stock Data

241.89M
65.38M
5.84%
49.85%
0.02%
Health Information Services
Healthcare
Link
United States of America
Rolle